Toddlers safely built a tolerance to small amounts of peanut proteins thanks to a simple skin patch, which helped prevent the progression of a potentially deadly allergy.

More than 70% of these toddlers could tolerate 3 or 4 peanut kernels after a 3-year course of treatment, say American scientists working to commercialize the skin patch.

The findings, from an FDA-registered, long-term, phase 3 clinical trial offer encouraging news for parents of the one child in 50 born every year with the susceptibility to peanut allergies.

The study found that a peanut patch treatment—called epicutaneous immunotherapy, or EPIT—continued to help toddlers safely build tolerance to peanuts over three years. It used the DBV Technologies Viaskin Peanut Patch , which delivers small amounts of peanut prot

See Full Page